PMID- 28125325
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20180402
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 137
IP  - 7
DP  - 2017 Jul
TI  - In vivo gene expression profiling for chemosensitivity to 
      docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell 
      carcinoma and the effect of TPF treatment on related gene expression in vitro.
PG  - 765-772
LID - 10.1080/00016489.2016.1272001 [doi]
AB  - CONCLUSION: These results provided a battery of genes relating to TPF 
      chemotherapeutic sensitivity and might act as molecular targets in laryngeal 
      squamous cell carcinoma (LSCC) treatment. Moreover, these candidate biomarkers 
      could contribute to LSCC individualized treatment. OBJECTIVES: To screen out a 
      set of candidate genes which could help to determine whether patients with LSCC 
      could benefit from TPF induction chemotherapy. METHOD: Gene-expression profiles 
      in seven TPF-sensitive patients were compared to four resistant controls by 
      microarray analysis. Subsequently, expression levels of potential biomarkers in 
      chemosensitive cell line UMSCC5 after TPF treatment were observed by qRT-PCR. 
      RESULTS: Through microarray analysis, 1546 differently expressed genes were 
      identified, of which 769 were up-regulated in TPF chemotherapy-responsive 
      tissues, whereas 777 were down-regulated. Gene ontology (GO) analysis suggested 
      these genes participating in physiological processes including cell 
      differentiation, metabolism, signal transduction, and cellular component 
      organization. Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) 
      database revealed that Wnt and p53 signaling pathways occupied important roles in 
      TPF chemotherapeutic sensitivity. Moreover, in vitro cell culture experiments 
      revealed the expression alternations of Mapk10, Jun, Vegfb, Pik3r5, Pld1, Tek, 
      Itga6 exposed to TPF treatment by qRT-PCR, whilst providing an insight into the 
      mechanism underlying TPF chemotherapeutic response in LSCC.
FAU - Lian, Meng
AU  - Lian M
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Shi, Qian
AU  - Shi Q
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Fang, Jugao
AU  - Fang J
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Feng, Ling
AU  - Feng L
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Ma, Hongzhi
AU  - Ma H
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Wang, Haizhou
AU  - Wang H
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren 
      Hospital, Capital Medical University , Beijing , PR China.
FAU - Zhang, Liang
AU  - Zhang L
AD  - b Key Laboratory of Otorhinolaryngology Head and Neck Surgery, Ministry of 
      Education , Beijing Institute of Otorhinolaryngology , Beijing , PR China.
FAU - Wang, Hong
AU  - Wang H
AD  - b Key Laboratory of Otorhinolaryngology Head and Neck Surgery, Ministry of 
      Education , Beijing Institute of Otorhinolaryngology , Beijing , PR China.
FAU - Ma, Zhihong
AU  - Ma Z
AD  - c Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology , 
      Beijing , PR China.
FAU - Liu, Honggang
AU  - Liu H
AD  - c Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology , 
      Beijing , PR China.
LA  - eng
PT  - Journal Article
DEP - 20170126
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Aged
MH  - *Antineoplastic Agents
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Carcinoma, Squamous Cell/drug therapy/*metabolism
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Wnt Signaling Pathway
OTO - NOTNLM
OT  - LSCC
OT  - TPF
OT  - chemotherapeutic sensitivity in vivo
OT  - gene expression alteration in vitro
OT  - microarray
EDAT- 2017/01/27 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/01/27 06:00
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/01/27 06:00 [entrez]
AID - 10.1080/00016489.2016.1272001 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2017 Jul;137(7):765-772. doi: 10.1080/00016489.2016.1272001. 
      Epub 2017 Jan 26.